On June 7 2021, the U.S. Food and Drug Administration (FDA) approved the drug Aducanumab, co-developed by Japanese pharmaceutical company Eisai and U.S.-based Biogen to treat Alzheimer’s disease. The drug is effective in removing amyloid beta, a protein which accumulates in large amounts in the brains of people with Alzheimer's disease.
Our resident news anchor delves into the current treatments for Alzheimer’s, and how the latest drug developed by Eisai and Biogen is different.
- Summary エーザイが共同開発した新薬、FDAで承認へ
- About the drug Aducanumab アデュカヌマブについて
- Current treatments for Alzheimer’s これまでのアルツハイマー治療薬
- Dementia among the Japanese elderly 日本の認知症患者数
- Conclusionまとめ
---
Watch the news video with Japanese transcript here!
https://perapera.ai/watch/youtube-u1vl8p6oN6U
---
This podcast episode is best listened to in conjunction with the following news video from FNN Prime Online.
エーザイなど共同開発のアルツハイマー病治療薬 世界初 米FDAが承認
https://youtu.be/u1vl8p6oN6U
FNN Prime Online YouTube Channel
https://www.youtube.com/user/FNNnewsCH
Disclaimer: News Anchor Japanese is not affiliated, associated, authorized, endorsed by, or in any way officially connected with Fuji News Network, Inc., or any of its subsidiaries or its affiliates. The official FNN Prime Online website can be found at https://www.fnn.jp/